United Therapeutics (UTHR) Deferred Taxes (2009 - 2026)

United Therapeutics (UTHR) reported Deferred Taxes of $25.9 million for Q1 2026, down 14.75% sequentially from $30.4 million in Q3 2012.

United Therapeutics (UTHR) Deferred Taxes (2009 - 2026) Analysis & Trends

United Therapeutics (UTHR) has 5 years of Deferred Taxes data on file, last reported at $25.9 million in Q1 2026.

For the quarter ending Q1 2026, Deferred Taxes changed N/A year-over-year to $25.9 million; the trailing twelve-month figure through Mar 2026 stood at $87.3 million (down 7.7% YoY), and the FY2025 full-year result was $97.7 million, up 252.42% from the prior year.
Deferred Taxes retreated to $25.9 million in Q1 2026, from $30.4 million in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $25.9 million in Q1 2026 to a low of $25.9 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-22.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	34.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	25.90 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	-69.70 Mn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-61.10 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Vireo Growth	10.57 Bn	10.41 Bn	59.30 Mn	2.20 Mn

Download Data